Viewray Inc (NASDAQ:VRAY) CEO Scott William Drake acquired 60,000 shares of the stock in a transaction dated Tuesday, November 13th. The shares were purchased at an average price of $6.47 per share, for a total transaction of $388,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of VRAY traded up $0.17 on Tuesday, reaching $6.28. 2,565,600 shares of the stock traded hands, compared to its average volume of 1,110,517. The stock has a market cap of $498.62 million, a PE ratio of -6.38 and a beta of 1.17. The company has a current ratio of 3.33, a quick ratio of 2.64 and a debt-to-equity ratio of 1.17. Viewray Inc has a 12 month low of $5.80 and a 12 month high of $13.21.

Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). Viewray had a negative net margin of 105.09% and a negative return on equity of 223.23%. The company had revenue of $17.70 million during the quarter, compared to the consensus estimate of $17.77 million. During the same quarter last year, the company earned ($0.19) earnings per share. The business’s revenue was up 45.1% on a year-over-year basis. Equities analysts forecast that Viewray Inc will post -0.8 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in VRAY. Fosun International Ltd grew its position in Viewray by 27.9% in the second quarter. Fosun International Ltd now owns 13,768,556 shares of the company’s stock valued at $95,278,000 after acquiring an additional 3,000,581 shares during the period. FMR LLC grew its position in Viewray by 36.9% in the second quarter. FMR LLC now owns 7,670,767 shares of the company’s stock valued at $53,082,000 after acquiring an additional 2,069,086 shares during the period. BlackRock Inc. grew its position in Viewray by 51.9% in the third quarter. BlackRock Inc. now owns 4,501,045 shares of the company’s stock valued at $42,130,000 after acquiring an additional 1,538,108 shares during the period. Artisan Partners Limited Partnership bought a new stake in Viewray in the second quarter valued at $6,852,000. Finally, Partner Fund Management L.P. bought a new stake in Viewray in the third quarter valued at $8,232,000. Hedge funds and other institutional investors own 85.98% of the company’s stock.

VRAY has been the topic of a number of research reports. BidaskClub upgraded Viewray from a “hold” rating to a “buy” rating in a research report on Friday, July 20th. ValuEngine cut Viewray from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 8th. BTIG Research restated a “buy” rating and set a $14.00 price objective on shares of Viewray in a research report on Tuesday, August 7th. Mizuho restated a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Monday, August 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Wednesday, October 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Viewray presently has a consensus rating of “Buy” and a consensus target price of $12.79.

TRADEMARK VIOLATION WARNING: “Viewray Inc (VRAY) CEO Scott William Drake Purchases 60,000 Shares” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/13/viewray-inc-vray-ceo-scott-william-drake-purchases-60000-shares.html.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Recommended Story: What is an Initial Public Offering (IPO)?

Insider Buying and Selling by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.